Francois Vigneault

Francois Vigneault is the current Co-Founder, President, and CEO of ShapeTX. Francois was previously the VP Research of Juno Therapeutics, Inc from January 2016 to May 2018. There, they oversaw the scientific strategy and development of technologies for the discovery of fully human T cell receptors (TCRs) and B cell immunoglobulins for the development of CAR-T immunotherapy against solid tumors. Prior to Juno, Francois was the Founder of AbVitro Inc from October 2012 to January 2016 where they pioneered high-throughput single cell sequencing for the development of therapeutics in oncology, autoimmunity and infectious diseases. Francois conceived and executed business strategy, hiring, lab building, etc. Raised $3MM Series A round. Completed a technology deal with Roche Molecular Sequencing in October 2014. The company was acquired by Juno therapeutics in January 2016 for $125MM in upfront considerations for a ~40x return on investment. Francois's experience also includes being a Post-doctoral Fellow / George Church Lab of Harvard Medical School from November 2007 to October 2013.

Francois Vigneault has a PhD in Molecular and Cellular Biology from Université Laval. Francois also has an M.Sc in Molecular and Cellular Biology from the same school, as well as a BSc in Microbiology.

Will Krause - VP, Finance, Rafael Ponce - EVP, Preclinical Development, and David Huss - CSO report to Francois Vigneault.